We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

15 hedge funds and large institutions have $23.3M invested in Theriva Biologics in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,355% more capital inflows, than outflows

Capital inflows: $742K | Capital outflows: $51K

0.99% more ownership

Funds ownership: 30.06% → 31.05% (+0.99%)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
+$481K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$261K

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$48K
2
UBS
UBS
Switzerland
-$3K

TOVX Hedge Fund Activity: Q3 2013 in Review

15 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2013, worth a combined $23.3M — up 0.89% from $23.1M a quarter earlier.

Fund positioning in TOVX was balanced in Q3 2013: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $481K. The largest seller was Wells Fargo, exiting entirely with an estimated $48K sold.

  • 15 institutional investors held Theriva Biologics (TOVX) as of Q3 2013, unchanged from Q2 2013.
  • Funds reported $23.3M of Theriva Biologics stock for Q3 2013, up 0.89% quarter-over-quarter.
  • 1 fund opened new Theriva Biologics positions in Q3 2013 and 1 closed out, a net change of 0 holders.
  • The largest Theriva Biologics buyer in Q3 2013 was Janney Montgomery Scott, an estimated $481K added.
  • The largest Theriva Biologics seller in Q3 2013 was Wells Fargo, an estimated $48K sold.

Based on aggregated 13F filings for Q3 2013.